Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that it has agreed to sponsor a human clinical trial of naturally occurring respiratory tract diseases, including influenza, with Dr. Manfred Beilharz, the Head of the Nobel Prize winning Department of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, the University of Western Australia. The trial will test whether daily dosing with oral interferon can protect human volunteers from infection and reduce the severity of respiratory tract infections, compared to placebo. The study is expected to start in Australia in early 2007 and continue for 6 months during which time 200 volunteers are expected to naturally encounter influenza viruses and other respiratory tract pathogens as they go about their daily lives. Dr. Beilharz will attend the ABI annual shareholder’s meeting held June 22, 2006 in Amarillo, Texas at the Days Inn, East 1701 E IH40 to discuss his research with oral interferon and influenza.
